Abstract PS6-44: The significance of body mass index and absolute lymphocyte count as a prognostic factor for disease-free survival in Korean breast cancer patients

Abstract

Abstract Introduction: The purpose of our study is to identify the association between body mass index (BMI) and absolute lymphocyte count (ALC), and to determine the effect of these two factors on the prognosis of breast cancer patients.Methods: We retrospectively identified 16,375 healthy female and 1,226 primary invasive breast cancer patients from Gangnam Severance Hospital. BMI and complete blood count (CBC) information at the time of diagnosed was collected. A multivariate Cox proportional hazard model was used to variable associated with disease-free survival (DFS).Results: BMI and ALC has positive correlation in breast cancer patients as well as health female (both P < .001). However, the effect of BMI and ALC on prognosis was the opposite. Overweight and obese had worse DFS (HR, 2.00; 95% CIs, 1.36-2.96; P < .001) than underweight or normal weight, but patients with high ALC had better DFS than those with low ALC (HR, 0.42; 95% CIs, 0.28-0.63; P < .001). When the risk stratification group was divided according to BMI /ALC, the high-risk group who had high BMI and low ALC had worse DFS than low-risk group (HR, 2.61; 95% CIs, 1.51-4.51; P = .001). In subgroup analysis, Her2-overexpressing and early stage tumor was more affected by BMI/ALC.Conclusions: The impact of BMI and ALC on prognosis in breast cancer was the opposite although BMI and ALC had positive correlation. Patients with high BMI and low ALC had worse DFS than others. Weight management is essential to breast cancer patients, and additional study about correlation between BMI and ALC affecting prognosis is needed in the future. Citation Format: Sung Min Ko. The significance of body mass index and absolute lymphocyte count as a prognostic factor for disease-free survival in Korean breast cancer patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-44.